Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).

The oncologist - 1 Dec 2020

Nosaki Kaname, Yamanaka Takeharu, Hamada Akinobu, Shiraishi Yoshimasa, Harada Taishi, Himeji Daisuke, Kitazaki Takeshi, Ebi Noriyuki, Shimose Takayuki, Seto Takashi, Takenoyama Mitsuhiro, Sugio Kenji

Abstract excerpt

LESSONS LEARNED: This phase II trial evaluated the efficacy of erlotinib for patients with non-small cell lung cancer with leptomeningeal metastasis. The 17 cerebrospinal fluid specimens that were available for epidermal growth factor receptor mutation analysis were all negative for the resistance-conferring T790M mutation. The cytological objective clearance rate was 30.0% (95% confidence interval: 11.9%-54.3%)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Quality of Life

Source

Open in PubMed Open full text

Identifiers

PMID: 32654250
DOI: 10.1634/theoncologist.2020-0640
PMCID: PMC8108053

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).PMID 32654250Read ↗

Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.Semantic proximity Read ↗

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.Semantic proximity Read ↗

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.Semantic proximity Read ↗

Leptomeningeal metastases in non-small-cell lung cancer.Semantic proximity Read ↗

Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).Semantic proximity Read ↗

Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review.Semantic proximity Read ↗

Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations.Semantic proximity Read ↗

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.Semantic proximity Read ↗

Real-world survival of EGFR-mutated NSCLC with leptomeningeal metastases: prognostic impact of TKIs and local multidisciplinary treatment from the CLM-tree registrySemantic proximity Read ↗

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.Semantic proximity Read ↗

High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.